Cargando…
Achieving clinical success with BET inhibitors as anti-cancer agents
The transcriptional upregulation of oncogenes is a driving force behind the progression of many tumours. However, until a decade ago, the concept of ‘switching off’ these oncogenic pathways represented a formidable challenge. Research has revealed that members of the bromo- and extra-terminal domain...
Autores principales: | Shorstova, Tatiana, Foulkes, William D., Witcher, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076232/ https://www.ncbi.nlm.nih.gov/pubmed/33723398 http://dx.doi.org/10.1038/s41416-021-01321-0 |
Ejemplares similares
-
BET inhibitors as novel therapeutic agents in breast cancer
por: Ocaña, Alberto, et al.
Publicado: (2017) -
The emerging role of BET inhibitors in breast cancer
por: Andrikopoulou, A., et al.
Publicado: (2020) -
Role of BET Inhibitors in Triple Negative Breast Cancers
por: Khandekar, Durga, et al.
Publicado: (2020) -
Are BET Inhibitors yet Promising Latency-Reversing Agents for HIV-1 Reactivation in AIDS Therapy?
por: Salahong, Thanarat, et al.
Publicado: (2021) -
Hawking bets against success
Publicado: (2008)